Guest writer Anita Newton discusses the difficult decisions that must be made as ALS progresses. None of them are easy.

Exposure to rhodamine B (RhB), a toxic fluorescent dye, causes neurodegeneration, symptoms that resemble ALS, and molecular ...

Far-field potentials (FFPs), nerve signals that can be measured on the skin, show promise as diagnostic and prognostic ...

Neuvivo and the FDA have agreed on a regulatory pathway for NP001 (sodium chlorite) to treat ALS, with Phase 3 testing ...

Columnist Dagmar Munn feels as if she's finding her voice again as she picks up her speech exercises, and then some.

In ALS, the loss of certain proteins turns off a gene called UNC13A that needs to stay active for nerve cell communication, a ...

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

Completing a project in her backyard was satisfying for columnist Kristin Neva, whose work as an ALS caregiver is repetitive and ongoing.

Columnist Kristin Neva shares what she feels has worked and not worked in terms of slowing her husband's ALS progression over 15 years.

The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.